Thiopurine S-methyltransferase Enzyme Activity (TPMT – Gene)

Overview

Thiopurine S-methyltransferase (TPMT) Enzyme Activity – Gene Test is a crucial diagnostic tool performed before starting thiopurine drug therapy. Thiopurines such as azathioprine, mercaptopurine, and thioguanine are used to treat autoimmune diseases and certain cancers. These drugs are metabolized into cytotoxic metabolites that can cause severe bone marrow toxicity if the TPMT enzyme is deficient. TPMT catalyzes the S-methylation of thiopurine drugs, regulating their activity and preventing toxic accumulation. Testing for Thiopurine S-methyltransferase activity or genetic variations ensures safe and effective therapy by guiding appropriate dosage adjustments and avoiding adverse drug reactions.

Symptoms

(Clinical signs that may prompt Thiopurine S-methyltransferase enzyme activity testing)

1. Low white blood cell (WBC) count after starting thiopurine therapy.
2. Signs of myelosuppression, such as recurrent infections, fatigue, and easy bruising.
3. Bone marrow toxicity, leading to anemia, leukopenia, or thrombocytopenia.
4. Gastrointestinal discomfort, nausea, or liver-related symptoms from poor drug metabolism.
5. Symptoms suggestive of lymphoma in patients on thiopurine therapy.
6. Unexplained treatment intolerance, where patients show exaggerated side effects to standard thiopurine doses.

Causes

(Factors influencing Thiopurine S-methyltransferase enzyme activity and the need for testing)

1. Genetic variations in the Thiopurine S-methyltransferase gene:
   1. Most individuals carry two normal “wild-type” alleles with normal enzyme activity.
   2. About 10% of individuals carry one normal allele and one variant allele, leading to intermediate activity.
   3. About 1 in 300 individuals carry two variant alleles (homozygous), resulting in little or no Thiopurine S-methyltransferase activity.
2. Enzyme deficiency: Lack of enzyme activity leads to accumulation of active thioguanine nucleotides, increasing the risk of myelosuppression.
3. Drug metabolism variability: Thiopurine S-methyltransferase activity determines how effectively thiopurine drugs are broken down, directly impacting therapeutic outcomes.
4. Bone marrow suppression: A direct result of cytotoxic metabolite build-up in individuals with Thiopurine S-methyltransferase deficiency.

Risk Factors

(Populations at higher risk of abnormal Thiopurine S-methyltransferase activity and thiopurine toxicity)

1. Patients are prescribed thiopurines, such as azathioprine or mercaptopurine, for conditions like inflammatory bowel disease, leukemia, or autoimmune disorders.
2. Individuals with genetic predispositions carrying TPMT variants predispose them to low or absent enzyme activity.
3. Patients showing intolerance to standard thiopurine doses are developing severe myelosuppression.
4. People with inflammatory bowel disease (IBD), who may require long-term thiopurine therapy, are at increased risk of colorectal tumors if TPMT activity is altered.
5. Children and adults undergoing chemotherapy, as thiopurine metabolism is critical for balancing therapeutic efficacy and toxicity.
6. Individuals with intermediate TPMT activity are at risk for dose-related complications if not monitored closely.

Prevention

(Strategies to reduce risks and ensure safe use of thiopurines)

1. Pre-treatment screening: Always test for TPMT enzyme activity or genotype before initiating thiopurine therapy.
2. Sample collection guidelines:
   1. Collect 6.0 ml of blood in EDTA lavender-capped tubes (3.0 ml in each).
   2. Alternatively, collect buccal swabs, ensuring they are air-dried and stored in a DNA stabilizing solution.
   3. Blood samples should be transported at ambient temperature with strict adherence to storage protocols.
3. Accurate detection methods:
   1. Phenotype testing: Measures enzyme activity levels in red blood cells.
   2. Genotype testing: Detects genetic variants affecting enzyme function.
   3. Thiopurine metabolite testing: Monitors drug breakdown products to adjust doses during therapy.
4. Interpretation of activity ranges:
   1. Normal activity > 21.0 EU/ml – no increased risk.
   2. Intermediate activity 21.0–65.0 EU/ml – moderate risk, requires careful dosing.
   3. Low activity < 6.0 EU/ml – high risk of toxicity, dose reduction or alternative treatment required.
5. Clinical monitoring: Regularly assess WBC counts, hemoglobin, and platelet levels during therapy.
6. Dose adjustment: Lower thiopurine doses or alternative therapies should be considered in patients with low or absent Thiopurine S-methyltransferase activity.
7. Genetic counseling: Advisable for patients with a family history of hematological disorders or known Thiopurine S-methyltransferase variants.
8. Education and awareness: Inform patients about the importance of monitoring, symptoms of toxicity, and adherence to prescribed regimens.